GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology.



 
01.07.14 GlycoVaxyn AG Announces the Initiation of a Phase I Clinical Trial in Collaboration with Janssen
12.06.14 GlycoVaxyn AG to Present at the FASEB Microbial Glycobiology Conference in Itasca, USA
04.06.14 GlycoVaxyn AG to Present at the IBC Bioconjugates Conference in San Francisco
 

GlycoVaxyn will be present during:

- FASEB Microbial Glycobiology Conference in Itasca on June 8-13, 2014

- IBC Bioconjugates Conference in San Francisco on June 4-6, 2014

- Glycobiology Symposium GlycoAR in Buenos Aires on April 24-25, 2014